Compare ALT & HIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALT | HIO |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 364.2M |
| IPO Year | 2005 | N/A |
| Metric | ALT | HIO |
|---|---|---|
| Price | $3.21 | $3.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 389.5K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.33% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $3.36 |
| 52 Week High | $7.73 | $4.05 |
| Indicator | ALT | HIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 31.51 |
| Support Level | $2.91 | N/A |
| Resistance Level | $4.25 | $3.91 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 1.18 | 0.00 |
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.